BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Myra, C
Right arrow Articles by Powell, R J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Myra, C
Right arrow Articles by Powell, R J
British Journal of Ophthalmology 2004;88:844-847
© 2004 BMJ Publishing Group Ltd

LETTER

Treatment of Erdheim-Chester disease with cladribine: a rational approach

C Myra1, L Sloper1, P J Tighe1,2, R S McIntosh2,3, S E Stevens2, R H S Gregson4, M Sokal5, A P Haynes6, R J Powell7

1 Division of Ophthalmology, University of Nottingham School of Clinical Laboratory Sciences, Queen’s Medical Centre, Nottingham NG7 2UH, UK
2 Division of Immunology, University of Nottingham School of Clinical Laboratory Sciences, Queen’s Medical Centre, Nottingham NG7 2UH, UK
3 Division of Ophthalmology, University of Nottingham School of Clinical Laboratory Sciences, Queen’s Medical Centre, Nottingham NG7 2UH, UK
4 Department of Diagnostic Imaging, Queen’s Medical Centre, Nottingham NG7 2UH, UK
5 Department of Oncology, City Hospital, Nottingham NG5 1PB, UK
6 Department of Haematology, City Hospital, Nottingham NG5 1PB, UK
7 Clinical Immunology Unit, Queen’s Medical Centre, Nottingham NG7 2UH, UK

Correspondence to:
Correspondence to:
C Myra L Sloper
Neuro-Ophthalmology Department, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; myra.sloper@dial.pipex.com

Accepted 5 November 2003

Keywords: Erdheim-Chester disease; cladribine; orbital pseudotumour; histiocytosis

The first 150 words of the full text of this article appear below.

Erdheim-Chester disease is a rare, life threatening lipoid granulomatosis1 with fewer than 100 cases described in the world literature. The disease typically affects the long bones and symmetrical sclerosis of the diaphyseal and metaphyseal regions is pathognomonic. Extraskeletal manifestations may affect the lungs, pericardium, aorta, retroperitoneum, skin, and orbits and diabetes insipidus occurs in approximately 30% of cases. Erdheim-Chester disease is characterised microscopically by an infiltrate of lipid laden foamy macrophages (histiocytes), scattered Touton giant cells, chronic inflammatory cells, and fibrosis. The foamy macrophages can be distinguished from Langerhans cells on the basis of negative results on staining for S-100 protein and CD1a. Treatment of the disease has been on an ad hoc basis and no treatment regimen has been shown to be clearly superior.

This study documents the clinical findings in a patient with Erdheim–Chester disease, investigates the pathogenesis, and provides a rational basis for effective treatment.


Case report
This white . . . [Full text of this article]




This article has been cited by other articles:


Home page
 BloodHome page
F. Braiteh, C. Boxrud, B. Esmaeli, and R. Kurzrock
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-{alpha}
Blood, November 1, 2005; 106(9): 2992 - 2994.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd.